PRACTICAL EVIDENCE FOR INFORMED PRACTICE CONFERENCE
See some of the sights of another great PEIP Conference. We thought it was great but don’t take our word for it read the post conference evaluations from our attendees. If you would like to attend other great PEER events sign up for the PEER Newsletter. Also, stay alerted to all PEER news and be the first to get the scoop on our 2023 PEIP Conference, October 20-21, 2023!
CFPCLearn’s primary care focused library includes a variety of content including evidence summaries, videos, podcasts and interactive learning courses to support clinicians in their practice.
Most Recent Tools for Practice
Tools for Practice #335 Asymptomatic bacteriuria in the elderly: Don’t drug the bugs?
In elderly, does asymptomatic bacteriuria (ASB) cause altered mental state and will treating ASB improve clinical outcomes?
Due to important evidence limitations, it is not confirmed that ASB, or even Urinary Tract Infection (UTI), is clearly associated with altered mental state. Treating ASB does not improve clinical outcomes (including altered mental state) but may increase adverse events from 1% to 7%. In elderly patients with ASB and altered mental state, antibiotics should be avoided without clear signs/symptoms of infection. Read More
Tools for Practice #334 – Wouldn’t Bet On it: What is the risk of muscle symptoms on statins?
What are the effects of statins on muscles?
Statins increase the risk of muscle symptoms (includes pain, cramps, and weakness) in their first year of use, from 14% (placebo) to 14.8%, but are similar to placebo after 1 year. When patients report muscle symptoms, only 1 in 15 is due to the statin. Statins may increase muscle symptoms with creatine kinase rise 10x normal for 1 in ~3000 patients over placebo. Read More
Tools for Practice #334 Wouldn’t Bet On it: What is the risk of muscle symptoms on statins?
What are the effects of statins on muscles?
Statins increase the risk of muscle symptoms (includes pain, cramps, and weakness) in their first year of use, from 14% (placebo) to 14.8%, but are similar to placebo after 1 year. When patients report muscle symptoms, only 1 in 15 is due to the statin. Statins may increase muscle symptoms with creatine kinase rise 10x normal for 1 in ~3000 patients over placebo. Read More
Tools for Practice #333 – Come Spy with Me: Continuous glucose monitoring in diabetes
Compared to self-monitoring blood glucose (SMBG), does continuous glucose monitoring improve clinical outcomes or HbA1c for adults with diabetes?
Continuous glucose monitors use subcutaneous sensors and include “real-time” and “flash” monitors (described below). Real-time monitors lower severe hypoglycemic events by 2-4% compared to SMBG (to ~6% from ~8%) in type 1 diabetes, with no reported events in type 2 diabetes. Effects on HbA1c may not be clinically meaningful. Compared to SMBG, flash monitors are no different on risk of severe hypoglycemia, and HbA1c effects are inconsistent (type 1) or no different (type 2). Cost may limit use. Read More
Tools for Practice TFP #332 – A Jab for Your CAD: Influenza vaccination for the prevention of cardiovascular events
Does influenza vaccination reduce the risk of cardiovascular events?
For every 100 patients vaccinated for influenza within about one month after an acute coronary syndrome, there will be 2 fewer cardiovascular events and 2 fewer deaths at one year compared to placebo. The impact of influenza vaccination in primary cardiovascular prevention and other cardiovascular conditions is less clear. Read More

PEER Values
When creating primary care education and programs, the PEER team focuses on minimizing bias, patient orientated outcomes, shared decision making, collaboration and most importantly simplicity.
Who is PEER?
Patients, Experience, Evidence and Research (PEER) was formed between a group of primary care providers who shared a common belief that evidence should be made accessible to all primary care providers.
